Sugi Predict

Sugi Predict / Compounds / SCHEMBL6683455

SCHEMBL6683455

SCHEMBL6683455

CC(C)(C(=O)NC1C2CC3CC1CC(C2)C3O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 8/20 0.56
▸ KMT2A Q03164 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HSD11B2 P80365 4/20 0.40
▸ HDAC3 O15379 2/20 0.40
▸ HDAC4 P56524 2/20 0.40
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC7 Q8WUI4 2/20 0.40
▸ HDAC2 Q92769 2/20 0.40
▸ HDAC10 Q969S8 2/20 0.40
▸ HDAC11 Q96DB2 2/20 0.40
▸ HDAC8 Q9BY41 2/20 0.40
▸ HDAC6 Q9UBN7 2/20 0.40
▸ HDAC9 Q9UKV0 2/20 0.40
▸ HDAC5 Q9UQL6 2/20 0.40
▸ ELOVL1 Q9BW60 1/20 0.37
▸ EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021692 0.87 HSD11B1 (0.64) HSD11B1KMT2AHSD11B2EPHX2
SCHEMBL6683411 0.84 HSD11B1 (0.55) HSD11B1KMT2AMAPTHSD11B2HDAC3
Ethylene SCHEMBL6688733 0.82 HSD11B1 (0.53) HSD11B1KMT2AMAPTHSD11B2HDAC3
SCHEMBL12585735 0.79 HSD11B1 (0.53) HSD11B1KMT2AMAPTHSD11B2HDAC3
SCHEMBL6683751 0.77 HSD11B1 (0.77) HSD11B1HSD11B2
SCHEMBL4826240 0.77 HSD11B1 (0.77) HSD11B1HSD11B2
SCHEMBL6683755 0.77 HSD11B1 (0.77) HSD11B1HSD11B2
SCHEMBL6683748 0.77 HSD11B1 (0.77) HSD11B1HSD11B2
SCHEMBL12585721 0.77 HSD11B1 (0.77) HSD11B1HSD11B2
SCHEMBL12585728 0.77 HSD11B1 (0.77) HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968601-B2 Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents JANSSEN PHARMACEUTICA N.V. (BE) 2011-06-28 — — US disclosed
US-7968601-B2 Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents JANSSEN PHARMACEUTICA N.V. (BE) 2011-06-28 — — US disclosed
US-20080096869-A1 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS LINDERS JOANNES T M 2008-04-24 — — US disclosed
US-20080096869-A1 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS LINDERS JOANNES T M 2008-04-24 — — US disclosed
US-7332524-B2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-19 — — US disclosed
US-7332524-B2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-19 — — US disclosed
WO-2004056744-A1 ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096869-A1 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS DHCR7, HSD3B2, HSD3B1 HSD11B1 5/4885KMT2A 3938/4885MAPT 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.